5th Circuit: FDA’s Post-2016 Mifepristone Actions Are Stayed Pending Appeal

Mealey's ( April 13, 2023, 2:27 PM EDT) -- NEW ORLEANS — A panel of the Fifth Circuit U.S. Court of Appeals on April 12 said anti-abortion plaintiffs are too late to challenge the Food and Drug Administration’s 2000 approval of the abortion drug mifepristone but left in place a district court stay of the agency’s related actions in 2016 pending an expedited appeal....